Taisho said to near $1.6 billion deal for Bristol-Myers"s UPSA: Bloomberg
Japanese healthcare firm Taisho Pharmaceutical Holdings Co Ltd is said to be close to a $1.6 billion deal for Bristol-Myers Squibb Co's French over-the-counter drugs business UPSA, Bloomberg reported on Sunday, citing sources familiar with the matter......»»
Bristol-Myers nears deal to sell French OTC drug unit to Taisho, Bloomberg says
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Bristol-Myers gets $1.6 billion offer for French consumer health unit
Bristol-Myers Squibb Co received an offer from Japanese healthcare firm Taisho Pharmaceutical Holdings Co Ltd to buy the company's French over-the-counter drugs business UPSA for $1.6 billion, the companies said on Wednesday......»»
Amgen to buy Celgene psoriasis drug Otezla for $13.4 billion
Amgen Inc will buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene by the end of the year......»»
Amgen to buy Celgene"s psoriasis drug Otezla for $13.4 billion in cash
Amgen Inc said on Monday it would buy Celgene Corp's psoriasis drug Otezla for $13.4 billion in cash, clearing the way for Bristol-Myers Squibb to go ahead with its $74 billion deal for Celgene......»»
Bristol-Myers Squibb Loses $6 Billion in Value on Celgene Deal Setback: Brainstorm Health
Bristol Myers surprised investors, announcing it would spin off Celgene's popular drug Otezla to address antitrust concerns. Happy Monday, readers! Bristol-Myers Squibb hasn’t exactly had a p.....»»
Bristol-Myers plans to divest Celgene"s psoriasis drug
Bristol-Myers Squibb Co on Monday offered to divest Celgene Corp's psoriasis treatment Otezla to allay concerns raised by the U.S. competition regulator, and pushed back the closing of their $74 billion deal......»»
Bristol to divest Celgene"s psoriasis treatment in FTC clearance push
Bristol-Myers Squibb Co said on Monday it would divest Celgene Corp's psoriasis treatment Otezla as the companies look to gain approval for their $74 billion deal from the U.S. Federal Trade Commission (FTC)......»»
Bristol-Myers says 75% of holders voted for Celgene deal, Bloomberg reports
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Bristol-Myers says shareholders vote to approve Celgene takeover
Bristol-Myers Squibb Co's shareholders voted to approve the drugmaker's $74 billion takeover of biotech Celgene Corp on Friday despite a campaign by activist hedge fund Starboard Value LP to scuttle the deal......»»
Bristol-Myers expected to win shareholder nod for Celgene deal, Bloomberg says
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Do Nektar’s disappointing clinical trial results invalidate $2 billion Bristol-Myers deal?
Bristol-Myers’ $1.85 billion deal with Nektar, announced in February, is predicated largely on the success of this exact combination of drugs......»»
Bristol-Myers receives offer from Taisho to purchase UPSA for $1.6B
See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»
Drugmaker Bristol-Myers to buy Celgene for $74 billion
Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion in a cash-and-stock deal, creating a powerhouse that will have several blockbuster cancer drugs......»»
Bristol-Myers to acquire Celgene in cash-and-stock deal with equity value of about $74 billion
Bristol Myers-Squibb Co. and Celgene Corp. said Thursday they have agreed to merge in a deal in which Bristol-Myers will acquire Celgene for cash and stock.....»»
Bristol-Myers to buy Celgene in a $74 billion deal
Bristol-Myers on Thursday announced plans to buy Celgene in a deal valued at $74 billion......»»
Bristol-Myers Squibb To Buy Celgene In $74 Billion Deal
Bristol-Myers Squibb To Buy Celgene In $74 Billion Deal.....»»
Bristol-Myers, Celgene to Tie a $74 Billion Knot
Bristol-Myers has announced a definitive agreement to acquire rival Celgene in a cash and stock deal worth $74 billion. Celgene shareholders are scheduled to receive a 54% premium to Wednesday........»»
Bristol-Myers bulks up cancer portfolio with $74 billion Celgene deal
Bristol-Myers Squibb Co said on Thursday it would buy Celgene Corp for about $74 billion, creating a major pharma company with several blockbuster cancer drugs as competition in the immunotherapy space heats up......»»
Bristol-Myers to buy Celgene in $74 billion deal
Bristol-Myers on Thursday announced plans to buy Celgene in a deal valued at $74 billion......»»